Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Chen P, Liu M, Li GY, Sun F, Li T. Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial. Ann Oncol 2024;35:140-141. [PMID: 37871700 DOI: 10.1016/j.annonc.2023.10.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/10/2023] [Accepted: 10/17/2023] [Indexed: 10/25/2023] Open

For:	Chen P, Liu M, Li GY, Sun F, Li T. Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial. Ann Oncol 2024;35:140-141. [PMID: 37871700 DOI: 10.1016/j.annonc.2023.10.128] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/10/2023] [Accepted: 10/17/2023] [Indexed: 10/25/2023] Open

Number

Cited by Other Article(s)

Liu M, Chen P, Li T. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. Eur Urol 2023:S0302-2838(23)03293-1. [PMID: 38135561 DOI: 10.1016/j.eururo.2023.11.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 11/09/2023] [Indexed: 12/24/2023]